Rodman & Renshaw Reiterates Buy on SAB Biotherapeutics, Maintains $13 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.7%

Neg 0% Neu 86.7% Pos 0%

Rodman & Renshaw analyst Seema Sheoran reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $13 price target.